Table 1 General data of the 31 AAV patients in active stage
Parameters | Value |
|---|---|
General clinical data | |
 No. subjects | 31 |
 Gender (M/F) | 19/12 |
 Age | 59.4 ± 13.2 |
 ANCA target antigen (MPO/PR3) | 29/3 |
 Initial Scr (μmol/L) | 448.6 ± 250.6 |
 Urinary protein (g/24 hr) | 0.76 (00.5–2.01) |
 BVAS | 18.3 ± 5.7 |
 Renal involvement | 21 (91.3%) |
 Pulmonary involvement | 21 (91.3%) |
 ENT involvement | 6 (26.1%) |
 Nervous system involvement | 5 (21.7%) |
Pathologic data | |
 No. subjects | 20 |
 Glomerular lesions | |
  Total crescents | 58% (36–77%) |
  Cellular crescents | 42% (26–57%) |
 Tubulointerstitial lesions | |
  Interstitial infiltration(−/+/++/+++) | 0/6/14/0 |
  Interstitial fibrosis(−/+/++) | 1/6/13 |
  Tubular atrophy(−/+/++) | 2/13/5 |
Treatment data | |
 Prednisone | 31 |
 Methylprednisolone pulse | 17 |
 Plasma exchange | 15 |
 CTX (intravenous/oral) | 28/3 |